EAErhan Ayhan

Erhan Ayhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erhan Ayhan has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sleep quality and temporomandibular joint function in psoriasis: a prospective controlled study

    by Ömer Karakoyun, Kadir Kaya, Zeynel Abidin Akar, Nur Ecer, Bahadır Aslancan, Erhan Ayhan

    Background: Psoriasis is a systemic inflammatory disease associated with sleep disturbance and musculoskeletal involvement. Data on temporomandibular joint (TMJ) function in psoriasis and its relationship with sleep quality, psoriatic arthritis (PsA) and systemic treatment are limited. We hypothesized that temporomandibular functional limitation would be associated primarily with PsA rather than with psoriasis itself, whereas sleep quality would relate mainly to cutaneous disease activity and treatment status. Objectives: To compare TMJ function and sleep quality between patients with psoriasis and healthy control participants, and to test whether these parameters differ according to PsA status and systemic treatment. Methods: This prospective controlled cross-sectional study included 105 patients with psoriasis and 73 age- and sex-matched healthy control participants. Patients were grouped as receiving no systemic therapy; receiving nonbiologic systemic therapy (methotrexate, acitretin or ciclosporin; no patient received an oral small-molecule agent such as apremilast or a tyrosine kinase 2 inhibitor); or receiving interleukin (IL)-17-/IL-23-targeted biologic therapy. No patient was receiving an anti-tumour necrosis factor (TNF) agent. Disease severity was assessed using Psoriasis Area and Severity Index (PASI), TMJ functional limitation using the 20-item Jaw Functional Limitation Scale (JFLS-20) and sleep quality using the Pittsburgh Sleep Quality Index (PSQI). Results: Global JFLS-20 scores did not differ significantly across healthy control participants and psoriasis treatment subgroups (P = 0.81). However, patients with PsA had higher mean (SD) JFLS-20 scores than those without PsA [0.80 (0.27) vs. 0.45 (0.22); P < 0.001]. PSQI scores were higher in patients who were not receiving systemic therapy or who were on nonbiologic systemic therapy, whereas patients treated with biologics, who also had markedly lower PASI scores, had scores comparable to healthy control participants. Poor sleep quality occurred in 60% (n = 25/42) and 60% (n = 12/20) of the no systemic treatment and nonbiologic systemic treatment groups compared with 10% (n = 7/73) of healthy control participants and 7% (n = 3/43) of patients treated with biologics. PASI correlated with PSQI (r = 0.49; P < 0.001), while PsA status independently predicted JFLS-20. Conclusions: Sleep impairment in patients with psoriasis was associated mainly with cutaneous disease activity and treatment status, whereas functional limitation of the TMJ was associated primarily with PsA rather than with psoriasis itself. As patients treated with biologics also had substantially lower disease activity, the better sleep quality in this group cannot be attributed to biologic therapy itself and may reflect lower disease burden and responder-related factors. As no patients on anti-TNF agents were included, these observations apply to IL-17- and IL-23-targeted agents rather than to biologics as a whole.

  • Open Access

    Real-World Effectiveness and Safety of Upadacitinib Versus Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Retrospective Cohort Study

    by Ömer Karakoyun, Erhan Ayhan

    Background: Janus kinase (JAK) inhibitors have expanded the therapeutic landscape for moderate-to-severe atopic dermatitis (AD), yet real-world comparative data on upadacitinib and abrocitinib remain limited. Objective: We aimed to compare the 24-week real-world effectiveness and safety of upadacitinib 30 mg and abrocitinib 200 mg in adult patients with moderate-to-severe AD, using EASI-75 as the primary efficacy endpoint, and to explore potential clinical factors associated with treatment response. Methods: This retrospective single-center study included adult patients with moderate-to-severe AD treated with upadacitinib 30 mg or abrocitinib 200 mg and followed for 24 weeks in routine clinical practice. A small pediatric subgroup (n = 3) receiving abrocitinib 100 mg was analyzed separately for descriptive purposes only. Clinical outcomes included Eczema Area and Severity Index (EASI), Peak Pruritus Numerical Rating Scale (PP-NRS), EASI-50/75/90 response rates, and NRS-4 response. Safety was assessed using routinely documented adverse events. Exploratory analyses evaluated the possible influence of body mass index (BMI), baseline immunoglobulin E (IgE), and psychological stress on treatment response. Results: Both upadacitinib and abrocitinib were associated with rapid and sustained clinical improvement over 24 weeks. At month 6, EASI-75 response was 83.3% in the upadacitinib group versus 70.8% in the abrocitinib group (p = 0.27). EASI-50 response was significantly higher in the upadacitinib group (100% vs. 83.3%; p = 0.05). Exploratory findings suggested that higher BMI, elevated baseline IgE levels, and psychological stress may be associated with less favorable response trajectories. Both treatments demonstrated a generally favorable safety profile; however, one serious cerebrovascular thrombotic event occurred in a patient with pre-existing cardiovascular risk factors, highlighting the importance of individualized risk assessment when prescribing JAK inhibitors. Conclusions: In routine clinical practice, both upadacitinib and abrocitinib appeared effective for the management of moderate-to-severe AD over 24 weeks. Although upadacitinib 30 mg showed a numerically higher month-6 EASI-50 response, this finding should be interpreted cautiously given the modest sample size and the absence of broader between-group differences across other key efficacy outcomes. Larger prospective studies are needed to confirm comparative effectiveness and to clarify predictors of response and safety in real-world settings.

  • Skin Infections

    by Erhan Ayhan, İsA An

  • Open Access

    The Impact of Mushroom Management on Nurses’ Job Satisfaction: The Mediating Role of Organizational Identification

    by Delal Aydın, Özcan Demir, Ömer Karakoyun, Nur Ecer, Erhan Ayhan

    Background: Mushroom management, a leadership style characterized by withholding information, excluding employees from strategic processes, and maintaining top‐down control, has been linked to adverse organizational outcomes. However, its impact on nurses and the psychological mechanisms through which this influence operates remain underexamined. Purpose: This study examines the direct and indirect effects of mushroom management on nurses’ job satisfaction, with organizational identification (OI) as the mediating variable, guided by affective events theory and social identity theory. Methods: A cross‐sectional survey was conducted with 317 nurses employed in private hospitals in Diyarbakır, Türkiye. Data were collected using validated Turkish versions of the Mushroom Management Scale (Birincioğlu and Tekin, 2018), Job Satisfaction Scale (Judge et al., 2008; Keser and Bilir, 2019), and Organizational Identification Scale (Mael, 1988; Tüzün and Özdoğan, 2006). All scales use a five‐point Likert format (1 = strongly disagree to 5 = strongly agree ). Confirmatory factor analysis confirmed good model fit ( χ 2 /d f = 2.21, CFI = 0.95, RMSEA = 0.062). Mediation was tested using Hayes’ PROCESS macro (Model 4) in SPSS 23.0 with 5000 bootstrap samples. Results: Mushroom management had significant negative effects on OI (standardized β = −0.46, p < 0.001) and job satisfaction (standardized β = −0.21, p = 0.001). OI positively predicted job satisfaction (standardized β = 0.48, p < 0.001). Mediation analysis confirmed a significant indirect effect (standardized β = −0.22, 95% CI [−0.31, −0.14]), with OI accounting for 51% of the total effect indicating partial mediation. Conclusions: Mushroom management is associated with lower OI and job satisfaction among nurses, with OI serving as a key identity‐based psychological mechanism. Healthcare leaders should prioritize transparent communication, participatory decision‐making, and identity‐affirming leadership practices to enhance nurse well‐being and retention. Implications for Nursing Management: Findings highlight the need for structured information‐sharing protocols, mushroom‐management–specific leadership training, and shared governance structures in private hospital settings. Periodic organizational climate monitoring using validated instruments is recommended.

  • Open Access

    Predictive role of inflammatory indexes in systemic manifestations of pediatric Behçet’s disease

    by Zeynel Abidin Akar, Ömer Karakoyun, Kadir Kaya, Erhan Ayhan

    Behçet's disease (BD) is a multisystem autoinflammatory disorder that may present during childhood. Pediatric BD is challenging to diagnose due to heterogeneous clinical manifestations and the lack of standardised pediatric classification criteria. This study aimed to evaluate the association between systemic inflammatory biomarkers-including the neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), pan-immune-inflammation value (PIV), and C-reactive protein (CRP)/albumin ratio-and systemic organ involvement in children with BD. To our knowledge, no prior study has investigated these markers in pediatric BD. In this retrospective study, 41 pediatric patients diagnosed with BD according to the 2015 PEDBD criteria and followed jointly by dermatology and rheumatology departments were included. Age- and sex-matched healthy controls (n = 41) undergoing elective surgery were also enrolled. Inflammatory indices (NLR, SII, PIV, CRP/albumin) were calculated from pre-treatment blood samples. Cut-off values for systemic involvement were determined via ROC analysis. Statistical analyses included the Kolmogorov-Smirnov test, independent t-test or Wilcoxon test, Chi-square and McNemar tests, correlation analysis, logistic regression, and ROC analysis. Systemic involvement was observed in 28 (68.3%) patients, including neurological involvement in 4 (9.8%), vascular involvement in 5 (12.2%), and other major organ involvement in 19 (46.3%). Inflammatory indices-PIV, SII, NLR, and CRP/albumin-were significantly higher in patients with systemic, neurological, and vascular involvement (all p < 0.05). Optimal cut-off values for each index were established based on systemic involvement. Systemic inflammatory biomarkers such as NLR, SII, PIV, and CRP/albumin ratio may serve as useful indicators of systemic organ involvement in pediatric BD. Routine assessment of these markers could facilitate earlier recognition and more targeted management of systemic manifestations in this population.


  • Open Access

    Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores

    by Merve Küçükşahin, Erhan Ayhan

    Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores - Turkish Journal of Dermatology

  • Open Access

    The Role of the Glass Ceiling Syndrome in Female Healthcare Workers and Its Association With Telogen Effluvium

    by Delal Aydın, Ömer Karakoyun, Erhan Ayhan

    Background‐Objective: Telogen effluvium (TE) type hair loss is the most common cause of diffuse and non‐scarring alopecia in women and may develop on the basis of many etiological causes. Glass ceiling syndrome, which is a popular research topic especially in recent years, is one of the syndromes that define the invisible barriers that women face in their careers and can cause long‐term stress during periods of exposure. Women working in the health sector are frequently exposed to the glass ceiling, and this situation has negative effects on skin health. The aim of the study is to investigate the relationship between glass ceiling syndrome‐induced stress and telogen effluvium, which has not been examined before. In addition, another aim of the study is to determine the effect of socio‐demographic variables such as age, gender, and education level on stress symptoms telogen effluvium. Materials and Methods: This study was conducted on 108 female participants working in University Hospitals. Questionnaires were used to determine how the participants experienced the glass ceiling syndrome, their professional and marital status, and their level of education. In addition, an examination including a pull test and trichoscopy for telogen effluvium disease was performed by specialized doctors. Results: 56 (51.85%) of 108 female health workers were diagnosed with telogen effluvium. It was determined that 73 (67.59%) of them had glass ceiling experience. Of the 108 female health workers, 36 were doctors, 44 were nurses, and 28 were other health workers. Regarding their education levels, 36 of them have a master's degree, 18 have a bachelor's degree, 34 have an associate's degree, and 20 have a high school degree. As for marital status, 71 of them were married, 24 of them were single, and 13 of them were divorced. A significant statistical relationship was found between telogen effluvium and glass ceiling syndrome and education and occupational status. At the same time, a significant statistical relationship was found between glass ceiling experience and education and occupational status. Conclusion: Glass ceiling syndrome is statistically significantly associated with telogen effluvium in female health workers, and it is emphasized that this situation should not be neglected as a source of intense stress during treatment. In addition, professional and marital status and education levels are also seen to feed this intense stress source.


  • Open Access

    Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa

    by Ömer Karakoyun, Erhan Ayhan

    Recently, adalimumab has become an important drug frequently used by dermatologists in the treatment of Hidradenitis suppurativa. While there are many publications by rheumatologists about the risk of hepatitis B and tuberculosis reactivation, the literature on reactivation in the treatment of hidradenitis is not extensive. With this study, we wanted to emphasize that adalimumab is a safe drug despite the risk of hepatitis B and tuberculosis reactivation and the importance of porphylaxis during the treatment of hidradenitis suppurativa. In this study, data from 462 HS patients followed up at the Dicle University Dermatology Clinic between 1 January 2017 and 30 June 2024 were retrospectively analyzed. Adalimumab use was detected in 56 of the 462 patients. Patients over 18 years of age and used adalimumab for at least 6 months were selected for this study. Two of these patients were not included in the study because they did not meet the criteria for age and duration of adalimumab use. All the participants were divided into 5 subgroups according to their HBV serological test results: natural immunity, chronic HBV infection, isolated anti-HBcIgG positivity, vaccinated and susceptible. Hepatitis B reactivation was detected only in those with positive anti-HBc IgG (chronic HBV infection, isolated anti-HBcIgG positivity, and natural immunity) tests who were at risk of reactivation. To investigate reactivation, HBV DNA test results before and after biological treatment and ALT-AST levels during the continuation of biological treatment were examined. Patients with a positive HBV DNA test before biological therapy and an increase of > 1 log10İU/ml in the HBV DNA titer during biological therapy and patients with a negative HBV DNA test before biological therapy and a positive HBV DNA test during the biological therapy use period were considered reactivation positive. Patients for whom no HBV DNA test was performed during the study period, those who had one positive HBV DNA test result before or after biological treatment and the other test result was not investigated, and those who had never been checked after starting biological treatment were not included in the reactivation investigation. For tuberculosis reactivation, those who had a latent tuberculosis test (quantitative test), did not report any symptoms and were chronic carriers were included. Among the patients with a positive latent TB test and suspicious clinical and radiological evaluation during biological treatment, those with a positive culture were considered reactivation positive. Of the 12 patients at risk of hepatitis B reactivation during adalimumab treatment, 8 received entecavir, and 4 received tenofovir prophylaxis. No hepatitis B reactivation was observed in any of the 12 patients during adalimumab treatment. Among the 54 patients, 4 were at risk of TB reactivation, and 4 received isoniazid as preophylactic treatment. None of the 4 patients were observed to have TB reactivation. Adalimumab has become a frequently preferred drug in the treatment of hidradenitis, and it is known that there is a risk of hepatitis b and TBc reactivation, which should be prevented. Despite these risks, we found that adalimumab can be safely used to treat hidradenitis suppurativa, especially with the use of prophylaxis.

  • Carbon footprint assessment of Energy-Based devices in clinical and aesthetic dermatology

    by Ömer Karakoyun, Erhan Ayhan, Delal Aydın

    Health care significantly contributes to global greenhouse gas emissions. Dermatology, particularly procedures involving energy-intensive devices such as lasers and light-based therapies, plays a notable role. To compare the per-session carbon footprint of commonly used aesthetic and clinical dermatologic devices and suggest strategies for sustainability. A descriptive life cycle assessment was conducted on 12 devices grouped as lasers, light-based tools, body-contouring systems, and alternative modalities. Device power data were sourced from manufacturers and literature; average session durations from clinical protocols. Energy use per session was calculated by multiplying power by session length and converted into CO₂ equivalents using Turkey’s national grid intensity (0.45 kg CO₂e/kWh). High-energy lasers (IPL, Nd: YAG, Alexandrite, CO₂) produced 0.30–0.70 kg CO₂e per session. LED therapy, microdermabrasion, and sonophoresis emitted < 0.01 kg CO₂e. Radiofrequency microneedling and EMS ranged between 0.10 and 0.70 kg CO₂e. Diode lasers offered up to 50% reduction due to higher energy efficiency. Dermatologic devices vary widely in carbon output. Choosing low-emission tools, optimizing session times, and utilizing teledermatology can significantly reduce environmental impact. Integrating sustainability metrics into device selection may support greener dermatologic practices.


  • Open Access

    Effect of ivermectin on scabies: a retrospective evaluation

    by Ömer Karakoyun, Erhan Ayhan, İsMail Yıldız

    Objective: This study, aimed at determining the effect of ivermectin on scabies, which has recently reached epidemic proportions, was conducted by the Department of Dermatology and Venereology at Dicle University. The study aims to evaluate the success of ivermectin in the treatment of scabies, identify variables affecting this success, and contribute positively to the development of future national treatment protocols. Additionally, the study seeks to test the hypothesis that ivermectin, which is significantly easier to use in cases of failure with topical treatments, is a good first-line treatment option. Materials and methods: In this retrospective study, 412 patients diagnosed with scabies via clinical examination by a specialist physician and recommended a 200 µg/kg dose of ivermectin at one-week intervals, who presented to Dicle University Dermatology and Venereology Clinic between January 1, 2023, and June 30, 2024, were examined. Fifty-two patients whose records lacked the parameters evaluated in the study were excluded. A total of 360 patients were included in the study. Data on children under five years of age, those weighing less than 15 kg, and pregnant or lactating women were not obtained due to insufficient information regarding oral ivermectin use in these groups. Data were evaluated with SPSS-21.0 statistical program and the value, mean, median value, standard deviation, incidence rate and frequency of each parameter in total patients were recorded. Associations were analysed using Kolmogorov-Smirnov test, dependent t test, Wilcoxon test, Pearson Chi-square (χ2) test, Yates Chi-square (χ2) test, Fisher Chi-square (χ2) test analysis, Mc-Nemar test, Pearson/spearman correlation analysis, logistic regression analysis. A p-value of < 0.05 was considered statistically significant. Results: The ivermectin treatments for all 360 patients were prescribed by a specialist physician, and 78.6% (283) of the patients benefited from the treatment. Of these 360 patients, 295 (81.94%) had tried at least one other treatment option before ivermectin and did not benefit from it, while 66.1% (43 out of 65) of those who had not previously undergone treatment benefited from ivermectin. Furthermore, 81.36% (240 out of 295) of patients who did not respond to previous treatments benefited from ivermectin. Conclusion: This study concluded that ivermectin could be a significant treatment option for patients diagnosed with scabies. The superiority of appropriately dosed ivermectin treatment over other treatments was observed, particularly in patients resistant to other scabies treatments.